Leerink analyst Mani Foroohar lowered the firm’s price target on Alnylam to $351 from $370 and keeps a Market Perform rating on the shares. Heading into 2026, the firm is refreshing its TTR market outlookafter strong launches from BridgeBio’s (BBIO) Attruby and Alnylam’s (ALNY) Amvuttra. Leerink expects continued robust growth in 2026, supported by end-market tailwinds from improved diagnosis rates leading to earlier treatment, but is keeping tabs on payer/reimbursement dynamics and pace of new patient adds/switches.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Nasdaq-100 Reshuffle: Who’s In, Who’s Out?
- Nasdaq adding Alnylam, Ferrovial, Insmed, Monolithic Power at open on 12/22
- Alnylam Pharmaceuticals: Hold Rating Due to Sales Projections Falling Short of Consensus
- Alnylam Pharma Announces Convertible Notes Buyback
- Alnylam price target raised to $508 from $495 at Stifel